Extended distribution agreement enables customers to continuously improve their bioprocesses

Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.

“Increasing demand for more targeted and personalized medicines is driving growth and development in the mAb manufacturing market. In combination with our industry-leading portfolio of downstream process equipment, Kaneka KanCapA 3G sorbent offers a complete solution to customers looking to make these products,” said Mario Philips, Vice President and General Manager at Pall Biotech. “Through the collaboration with the Kaneka team we are able to ensure consistency, quality and reliability with an industry-leading sorbent that enables customers to continuously improve their bioprocesses.”

The full Kaneka KanCapA line of products is based on a robust matrix that enables the high productivity affinity capture of mAbs and related biomolecules using a proprietary alkali stable rPrA ligand. Designed with a combination of proprietary recombinant ligand and a highly cross-linked cellulose base matrix, the new Kaneka KanCapA 3G sorbent exhibits enhanced binding capacity, an excellent elution profile, and advanced impurity removal properties when compared with other market sorbents.